

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

PE/Cyanine7 anti-human/mouse Granzyme B Recombinant

RRID:AB_2728380

Type: Antibody

Proper Citation

BioLegend Cat# 372213, RRID:AB_2728380

Antibody Information

URL: http://antibodyregistry.org/AB_2728380

Proper Citation: BioLegend Cat# 372213, RRID:AB_2728380

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: PE/Cyanine7 anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2728380

Vendor: BioLegend

Catalog Number: 372213

Alternative Catalog Numbers: 372214

Record Creation Time: 20231110T033638+0000

Record Last Update: 20260829T115023+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human/mouse Granzyme B Recombinant.

No alerts have been found for PE/Cyanine7 anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer immunology research, 14(8), 1292.

Zhang Y, et al. (2026) Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice. Cell host & microbe, 34(2), 212.

Wang H, et al. (2026) Targeting TMED4 enhances CD8+ T cell function and CAR T cell efficacy in solid tumors through the IRE1?-autophagy axis. Science advances, 12(24), eaee0517.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer cell, 43(3), 503.

Ingels J, et al. (2024) Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell reports. Medicine, 5(5), 101516.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell reports, 43(5), 114141.

Shi W, et al. (2024) Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell reports. Medicine, 5(5), 101531.

Fan H, et al. (2023) Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature, 623(7989), 1034.